PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

Journal of Clinical Oncology

Volumn 30, Issue 8, 2012, Pages 777-782

  Janku, Filip ^a   Wheler, Jennifer J ^a   Westin, Shannon N ^a   Moulder, Stacy L ^a   Naing, Aung ^a   Tsimberidou, Apostolia M ^a   Fu, Siqing ^a   Falchook, Gerald S ^a   Hong, David S ^a   Garrido Laguna, Ignacio ^a   Luthra, Rajyalakshmi ^a   Lee, J Jack ^a   Lu, Karen H ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DNA; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATINUM DERIVATIVE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; TAXANE DERIVATIVE; TEMSIROLIMUS;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; ENDOMETRIUM CANCER; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; MOLECULARLY TARGETED THERAPY; OVARY CANCER; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTO ONCOGENE; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES; UTERINE CERVICAL NEOPLASMS;

EID: 84863338519     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.1196     Document Type: Article

References (30)

1. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001 (Pubitemid 32267972)
2. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002 (Pubitemid 34879334)
3. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
4. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
5. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
6. Samuels Y, Wang Z, Bardelli A, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554, 2004 (Pubitemid 38541907)
7. Kang S, Bader AG, Vogt PK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 102:802-807, 2005 (Pubitemid 40282746)
8. Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer 9:550-562, 2009
9. Levine DA, Bogomolniy F, Yee CJ, et al: Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11:2875-2878, 2005 (Pubitemid 40525186)
10. Janku F, Tsimberidou A, Garrido-Laguna I, et al: PIK3CA, KRAS, and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. J Clin Oncol 28:224s, 2010 (suppl; abstr 2583)
11. Miyake T, Yoshino K, Enomoto T, et al: PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences. Cancer Lett 261:120-126, 2008
12. Hayes MP, Wang H, Espinal-Witter R, et al: PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 12:5932-5935, 2006 (Pubitemid 44703751)
13. Ihle NT, Lemos R Jr, Wipf P, et al: Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69:143-150, 2009
14. Di Nicolantonio F, Arena S, Tabernero J, et al: Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120:2858-2866, 2010
15. Engelman JA, Chen L, Tan X, et al: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351-1356, 2008
16. Zuo Z, Chen SS, Chandra PK, et al: Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol 22:1023-1031, 2009
17. Morony JW, Schlumbrecht MP, Helgason T, et al: A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res 17:6840-6846, 2011
18. Jimeno A, Herbst RS, Falchook GS, et al: Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. J Clin Oncol 28:255s, 2010 (suppl; abstr 3089)
19. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
20. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002 (Pubitemid 34716871)
21. Janku F, Tsimberidou AM, Garrido-Laguna I, et al: PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitor. Mol Cancer Ther 10:558-565, 2011
22. Horstmann E, McCabe MS, Grochow L, et al: Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895-904, 2005 (Pubitemid 40300298)
23. Jain RK, Lee JJ, Hong D, et al: Phase I oncology studies: Evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 16:1289-1297, 2010
24. Kurzrock R, Benjamin RS: Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med 352:930-932, 2005 (Pubitemid 40300304)
25. Moroney J, Wheler J, Hong D, et al: Phase I clinical trials in 85 patients with gynecologic cancer: The M. D. Anderson Cancer Center experience. Gynecol Oncol 117:467-472, 2010
26. Forbes SA, Tang G, Bindal N, et al: COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Res 38:D652-D657, 2010
27. Sequist LV, Martins RG, Spigel D, et al: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26:2442-2449, 2008
28. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
29. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001 (Pubitemid 33055745)
30. Janku F, Garrido-Laguna I, Wheler JJ, et al: Screening for PIK3CA mutations, PTEN loss, and RAS/RAF mutations in early-phase protocols with PI3K/mTOR pathway inhibitors. J Clin Oncol 29: 631s, 2011 (suppl; abstr 10507)